Genetic Syndromes and Radiotherapy in Breast Cancer
In this article, the controversial issue of breast-conserving therapy (lumpectomy followed by whole breast irradiation) is reviewed. Given the relatively recent identification of the BRCA1 and BRCA2 genes in the mid-1990s, the expense associated with testing, and the inherent selection biases, the available literature has inherent limitations with relatively small patient numbers and lack of prospective randomized trials in this subset of patients. However, a number of retrospective and case–control studies have demonstrated acceptable results with breast-conserving surgery and radiation, though without active prophylactic measures to reduce secondary malignancies late local in-breast relapses and contralateral secondary breast cancer events remain an issue. Acknowledging the limitations in the available data, there does not appear to be any evidence of compromised normal tissue reactions or compromised long-term survival rates in women electing breast-conserving surgery and radiation.
KeywordsBreast Cancer Cystic Fibrosis Transmembrane Conductance Regulator Contralateral Breast Cancer Breast Conservation Therapy BRCA Carrier
- Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304–2311CrossRefPubMedGoogle Scholar
- Vrieling C, Collette L, Fourquet A et al (1999) The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC radiotherapy and breast cancer cooperative groups. European organization for research and treatment of cancer. Int J Radiat Oncol Biol Phys 45:677–685CrossRefPubMedGoogle Scholar
- Vrieling C, Collette L, Fourquet A et al (2000) The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC radiotherapy and breast cancer cooperative groups. Radiother Oncol 55:219–232CrossRefPubMedGoogle Scholar